TickerTalks
Browse all tickers →
TickerTalks›$NVS
NVNVS

Novartis AG

$NVS·$295B·Drug Manufacturers - General·Healthcare
$159.85+2.4%YTD+12.9%1Y+34.4%
Mentions · last 7 days
2026-07-20: 26 posts2026-07-21: 101 posts2026-07-22: 11 posts2026-07-23: 10 posts2026-07-24: 3 posts2026-07-25: 1 posts2026-07-26: 3 posts155-3%
Price updated 8m ago·X counts updated 2d ago
NVNVS
$NVSNovartis AG
$159.85+2.40%155 posts-3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NVS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-07-25

The move is getting stronger, with heavier trading behind it.

Novartis just beat Q2 with 43-89% growth on its key oncology and cardio drugs — the pipeline is now driving the multiple.

Novartis is a Swiss-headquartered Big Pharma focused on innovation-driven medicines across oncology, immunology, and cardiovascular disease. Shares are up 12% year-to-date and 32% over twelve months at the 73rd percentile of the 52-week range, and the July 21 Q2 beat is the specific event that keeps the accelerating trajectory intact.

  • Q2 was a genuine beat: non-IFRS EPS of $2.41 beat $2.17 estimates on revenue of $14.41B versus $14.07B — with growth-driver drugs delivering at constant currencies: Kisqali +43%, Scemblix +89%, Pluvicto +43% (all oncology), and Leqvio +59% (cholesterol) — top-line growth that supports a 23x PE for mature pharma.
  • Management reaffirmed FY26 guidance and outlined M&A appetite: CEO Vas commented that Novartis will continue to look for acquisitions particularly under $2B while remaining open to larger deals — the capital-allocation stance supports both continuing organic growth and potential bolt-on acquisitions to extend the pipeline.
  • The pipeline is genuinely broad: BofA maintains Buy on the strength of remibrutinib (multiple sclerosis), del-desiran (Duchenne muscular dystrophy), and pelacarsen (cardiovascular) readouts — three distinct catalyst events over the coming quarters, and any positive readout re-rates the multiple higher.
  • Fundamentals are best-in-Big-Pharma: 74% gross margin, 30% operating margin, and 13.4% return on invested capital — Novartis has the operational quality of a growth-pharma with the yield-and-buyback profile of a mature name, and the 5.5% FCF yield funds a competitive dividend plus continued M&A.

October 27 Q3 earnings is the next real hurdle — a beat with continued growth-driver-drug momentum plus specific commentary on any of the pipeline readouts extends this leg toward $170+; a Kisqali or Scemblix growth deceleration or a pipeline setback stalls the recovery.

Agrees with X sentimentX is bullish on the Q2 beat and the pipeline commentary, and I fully agree — the growth-driver drugs are delivering, management is capitalizing on the momentum with M&A commentary, and the BofA Buy rating is validated by the multi-catalyst pipeline; the crowd's read is well-supported by the operational trajectory and the analyst positioning.

What to watch: October 27 Q3 2026 earnings and pipeline readouts on remibrutinib, del-desiran, and pelacarsen — the deciding developments are continued growth-driver momentum, any pipeline readout, and M&A activity; a competitive-response commentary on Leqvio or a Pluvicto safety signal is the near-term risk.

On the calendar: 2026-10-27 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment19 posts analyzed · as of 2026-07-27

Novartis beat Q2 with $14.41B revenue up 3% YoY, core EPS of $2.41 vs $2.20 estimate, and Kesimpta grew 32% as the company returned to growth despite patent-cliff concerns. CEO signaled openness to acquisitions particularly under $2B with larger deals possible, and full-year guidance was reaffirmed. Sentiment leans clearly bullish.

Read the AI verdict + X sentiment for $NVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $NVS.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+21.0%YTD
+49.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
23.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
29.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
29.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
74.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 21, 2026$2.41$2.17+11.1%
Q1 2026Apr 28, 2026$1.99$2.11-5.7%
Q4 2025Feb 4, 2026$2.03$1.99+2.0%
Q3 2025Oct 28, 2025$2.25$2.26-0.4%
Next earningsTue, Oct 27·consensus EPS $2.26

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$13.5B-0.7%74.4%31.3%$1.65$2.9B
Q4 FY25$13.3B-1.6%73.4%26.4%$1.26$1.6B
Q3 FY25$14.4B+9.0%75.4%31.3%$2.04$5.7B
Q2 FY25$14.8B+15.3%77.6%32.8%$2.07$6.1B

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$56.9B$56.3B – $58.0B$8.73$8.61 – $8.8813
FY27$60.5B$59.8B – $61.6B$9.74$9.53 – $10.0413
FY28$64.3B$63.2B – $66.3B$10.77$10.52 – $11.208
FY29$67.3B$66.1B – $69.3B$11.71$11.44 – $12.1712
FY30$70.6B$69.4B – $72.7B$12.85$12.56 – $13.366

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.75%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.8B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.495-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Mar 17424B5
424B5Prospectus supplement (offering)Mar 16424B5
+ 9 other (6 6-Ks · 1 S-8 · 1 IRANNOTICE · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

12,359 Shares in Novartis AG $NVS Bought by Entropy Technologies LPdefenseworld.net·2d agoCetera Investment Advisers Buys 24,096 Shares of Novartis AG $NVSdefenseworld.net·2d agoNovartis: The Buy Thesis Is Back (Rating Upgrade)seekingalpha.com·6d agoNovartis AG (NVS) Q2 2026 Earnings Call Transcriptseekingalpha.com·7d agoNovartis CEO on 2Q Profit Beat, Investing in Pipelineyoutube.com·7d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$MRK$PFE$BMY$ABBV$GILD
Voices on X · top 5 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport